KDM1A and small cell lung carcinoma: There is also a phase I/II trial evaluating the efficacy of the LSD1 inhibitor bomedemstat in combination with the anti-PD-L1 drug atezolizumab in patients with extensive-stage small-cell lung cancer (ES-SCLC) (NCT05191797).